Two separate pilot studies have determined the in vivo survival of Megaflora 9 evo bacteria.
Survival of Bifidobacterium
In the first study, the survival of Bifidobacterium was tested in 23 medical students from the University of Wageningen. The study was randomized double-blind controlled versus placebo with a dosage of 4 g of Megaflora 9 evo or placebo per day divided in 2 doses for 7 days.
At the beginning and at the end of the study stool samples were analyzed by PCR, DGGE and FISH. The results showed that students who consumed Megaflora 9 evo presented a clear difference in the population of bifidobacteria in the faeces compared to the placebo group, evidenced by the DGGE profile.
The image shows the DGGE results of nine students, 6 consuming Megaflora 9 evo (M9E) and 3 consuming placebo (P). It can be appreciated that students M9E-1 and M9E-7 presented specific markers for bifidobacteria at day 7 after consumption of Megaflora 9 evo compared with baseline (red circles).
These results demonstrate the survival of Bifidobacterium of Megaflora 9 evo in the gastrointestinal tract.
Survival of Lactobacillus
In the second study, 100 medical students from the University of Maastricht participated in a randomized double-blind controlled study versus placebo. The students were equally divided into two groups that were given Megaflora 9 evo or placebo.
The duration of the study was 8 days during which students consumed a dose of 3.8 g of Megaflora 9 evo or placebo divided by 2 times a day. The aim of the study was to check the survival of lactobacilli present in the faeces after ingestion.
The result showed a significant difference of lactobacilli in the faeces of students who consumed Megaflora 9 evo, demonstrating the survival of the bacteria after the GI passage.